Table 1.
Baseline characteristics of study patients receiving montelukast and placebo (n = 100)
| Number |
Montelukast |
Placebo |
|---|---|---|
| 50 | 50 | |
| Age in years (SD) |
50.50 ± 18.26 |
52.68 ± 18.86 |
| Male: Female (n) |
7:43 |
14:36 |
| Asthma history |
|
|
| a. Past history of sudden severe exacerbations |
22 (44%) |
22 (44%) |
| b. > 2 admissions |
17 (34%) |
11 (22%) |
| c. ICU admissions |
03 (06%) |
06 (12%) |
| d. Prior intubation |
01 (02%) |
04 (08%) |
| Family history of Asthma |
30 (60%) |
27 (54%) |
| Medication history |
|
|
| a) Fluticasone 250 mcg + Salmeterol 25 mcg |
24 (48%) |
25 (50%) |
| b) Oral Theophylline |
07 (14%) |
11 (22%) |
| c) Inhaled anti-cholinergic |
01 (02%) |
02 (04%) |
| Precipitating factors |
|
|
| a) Infection |
23 (46%) |
22 (44%) |
| b) Weather change |
27 (54%) |
24 (48%) |
| c) Non-compliance to drugs |
01 (02%) |
01 (02%) |
| d) Allergen exposure |
07 (14%) |
10 (20%) |
| f) None |
04 (07%) |
02 (04%) |
| Smoking status |
|
|
| a) Non-smoker |
47 (94%) |
42 (84%) |
| b) Current smoker |
02 (04%) |
03 (06%) |
| c) Ex-smoker |
01 (02%) |
05 (10%) |
| Additional therapy |
|
|
| a) IV aminophylline |
03 (06%) |
02 (04%) |
| b) IV magnesium sulphate |
16 (32%) |
15 (30%) |
| c) Oral theophylline | 10 (20%) | 16 (32%) |